Latest filings (excl ownership)
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Mar 24
8-K
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
30 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
7 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
28 Sep 23
ARS
2022 FY
Annual report to shareholders
16 Aug 23
DEF 14A
Definitive proxy
16 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update
11 May 23
8-K
Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
27 Mar 23
8-K
Regulation FD Disclosure
21 Mar 23
S-3ASR
Automatic shelf registration
28 Feb 23
S-8
Registration of securities for employees
28 Feb 23
8-K
Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Regulation FD Disclosure
20 Dec 22
CT ORDER
Confidential treatment order
29 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update
10 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
29 Sep 22
8-K
Regulation FD Disclosure
14 Sep 22
DEF 14A
Definitive proxy
16 Aug 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Altimmune Announces Second Quarter 2022 Financial Results and Provides a Business Update
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
12 May 22
S-8
Registration of securities for employees
15 Mar 22
10-K
2021 FY
Annual report
15 Mar 22
8-K
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
15 Mar 22
8-K
Termination of a Material Definitive Agreement
17 Dec 21
8-K
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer
13 Dec 21
8-K
Altimmune Announces Third Quarter 2021 Financial Results
9 Nov 21
10-Q
2021 Q3
Quarterly report
9 Nov 21
8-K
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of
28 Sep 21
8-K
Submission of Matters to a Vote of Security Holders
24 Sep 21
DEF 14A
Definitive proxy
16 Aug 21
Latest ownership filings
SC 13G/A
STATE STREET CORP
10 Apr 24
SC 13G
MILLENNIUM MANAGEMENT LLC
5 Mar 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Nuveen Asset Management, LLC
14 Feb 24
SC 13G/A
TEACHERS ADVISORS, LLC
14 Feb 24
SC 13G/A
TIAA CREF INVESTMENT MANAGEMENT LLC
14 Feb 24
SC 13G
AMERIPRISE FINANCIAL INC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
4
M Scot Roberts
5 Feb 24
4
Matthew Scott Harris
5 Feb 24
4
Vipin K Garg
5 Feb 24
4
M Scot Roberts
1 Feb 24
4
Raymond M Jordt
1 Feb 24
4
Matthew Scott Harris
1 Feb 24
4
Vipin K Garg
1 Feb 24
4
Richard I Eisenstadt
1 Feb 24
4
M Scot Roberts
29 Jan 24
4
Raymond M Jordt
29 Jan 24
4
Matthew Scott Harris
29 Jan 24
4
Vipin K Garg
29 Jan 24
4
Richard I Eisenstadt
29 Jan 24
SC 13G
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
Raymond M Jordt
4 Jan 24
4
Richard I Eisenstadt
2 Jan 24
4
David Drutz
29 Sep 23
4
Philip Hodges
29 Sep 23
4
Catherine A. Sohn
29 Sep 23
4
JOHN GILL
29 Sep 23
4
MITCHEL SAYARE
29 Sep 23
4
Diane Jorkasky
29 Sep 23
4
Wayne Pisano
29 Sep 23
4
Klaus Schafer
29 Sep 23
4
David Drutz
15 Aug 23
4
Vipin K Garg
2 Aug 23
4
Richard I Eisenstadt
2 Aug 23
4
Matthew Scott Harris
2 Aug 23
4
M Scot Roberts
2 Aug 23